Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1)

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 250-260

  Yang, Jiao ^a   Sun, Ke Kang ^a   Lin, Zhao ^a   Xu, Jia Ying ^a   Wang, Li Li ^a   Fan, Sai Jun ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

carcinogenesis; human lung cancer cells; metastasis; PTEN; RNA interference; transducer of ErbB 2.1 (TOB1)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; METASTASIS; PROTEIN EXPRESSION; TRANSDUCER; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY;

CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84863126968     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.163     Document Type: Article

References (56)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Inamura K, Ishikawa Y. Lung cancer progression and metastasis from the prognostic point of view. Clin Exp Metastasis 2010; 27: 389-97.
3. Mihaljevic AL, Michalski CW, Friess H, Kleeff J. Molecular mechanism of pancreatic cancer - understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 2010; 395: 295-308.
4. Hoon DS, Ferris R, Tanaka R, Chong KK, Alix-Panabieres C, Pantel K. Molecular mechanisms of metastasis. J Surg Oncol 2011; 103: 508-17.
5. Andjelkovic T, Bankovic J, Stojsic J, Milinkovic V, Podolski-Renic A, Ruzdijic S, et al. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 2011; 157: 19-28.
6. Yoneda M, Suzuki T, Nakamura T, Ajima R, Yoshida Y, Kakuta S, et al. Defciency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma. Cancer Sci 2009; 100: 225-32.
7. Mukhopadhyay UK, Mooney P, Jia L, Eves R, Raptis L, Mak AS. Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion. Mol Cell Biol 2010; 30: 4980-95.
8. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, et al. A nonreplicating adenoviral vector that contains the wildtype p53 transgene combined with chemotherapy for primary breast cancer: safety, effcacy, and biologic activity of a novel gene-therapy approach. Cancer 2006; 107: 935-44. (Pubitemid 44291141)
9. Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, Yoshida M, Emi M, Nakamura Y, et al. Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene 1996; 12: 705-13.
10. Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 2010; 222: 66-72.
11. Wang XM, Gao X, Zhang XH, Tu YY, Jin ML, Zhao GP, et al. The negative cell cycle regulator, Tob (transducer of ErbB-2), is involved in motor skill learning. Biochem Biophys Res Commun 2006; 340: 1023-7. (Pubitemid 43083381)
12. Jia S, Meng A. Tob genes in development and homeostasis. Dev Dyn 2007; 236: 913-21. (Pubitemid 46641333)
13. Mauxion F, Chen CY, Seraphin B, Shyu AB. BTG/TOB factors impact deadenylases. Trends Biochem Sci 2009; 34: 640-7.
14. Yoshida Y, Nakamura T, Komoda M, Satoh H, Suzuki T, Tsuzuku JK, et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev 2003; 17: 1201-6. (Pubitemid 36583162)
15. Iwanaga K, Sueoka N, Sato A, Sakuragi T, Sakao Y, Tominaga M, et al. Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett 2003; 202: 71-9. (Pubitemid 37464900)
16. Ito Y, Suzuki T, Yoshida H, Tomoda C, Uruno T, Takamura Y, et al. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett 2005; 220: 237-42. (Pubitemid 40568781)
17. Yoshida Y, von Bubnoff A, Ikematsu N, Blitz IL, Tsuzuku JK, Yoshida EH, et al. Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signaling. Mech Dev 2003; 120: 629-37.
18. Helms MW, Kemming D, Contag CH, Pospisil H, Bartkowiak K, Wang A, et al. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Cancer Res 2009; 69: 5049-56.
19. Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 2000; 103: 1085-97. (Pubitemid 32037395)
20. Wu QF, Liu C, Tai MH, Liu D, Lei L, Wang RT, et al. Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin 2010; 31: 361-6.
21. Li XL, Meng QH, Fan SJ. Adenovirus-mediated expression of UHRF1 reduces the radiosensitivity of cervical cancer HeLa cells to gammairradiation. Acta Pharmacol Sin 2009; 30: 458-66.
22. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Adenovirus-mediated expression of Tob1 sensitizes breast cancer cells to ionizing radiation. Acta Pharmacol Sin 2007; 28: 1628-36. (Pubitemid 47493295)
23. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007; 28: 1045-56. (Pubitemid 47020494)
24. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metallo-proteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007; 13: 2054-60.
25. Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T, Wakigawa T, et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-alpha, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflammation 2011; 8: 106.
26. O'Malley S, Su H, Zhang T, Ng C, Ge H, Tang CK. TOB suppresses breast cancer tumorigenesis. Int J Cancer 2009; 125: 1805-13.
27. Yanagie H, Tanabe T, Sumimoto H, Sugiyama H, Matsuda S, Nonaka Y, et al. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model. Biomed Pharmacother 2009; 63: 275-86.
28. Park GT, Seo EY, Lee KM, Lee DY, Yang JM. Tob is a potential marker gene for the basal layer of the epidermis and is stably expressed in human primary keratinocytes. Br J Dermatol 2006; 154: 411-8. (Pubitemid 43382645)
29. Tzachanis D, Boussiotis VA. Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. Cell Cycle 2009; 8: 1019-25.
30. Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol 2010; 2: a003236.
31. Hurst DR, Welch DR. Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 2011; 286: 107-80.
32. Lin ML, Lu YC, Chung JG, Wang SG, Lin HT, Kang SE, et al. Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog 2010; 49: 783-97.
33. Wang S, Cheng Z, Yang X, Deng K, Cao Y, Chen H, et al. Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. Int J Hematol 2010; 92: 83-94.
34. Abou Youssif T, Fahmy MA, Koumakpayi IH, Ayala F, Al Marzooqi S, Chen G, et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011; 117: 290-300.
35. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
36. Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, Bibeau F, Boissière-Michot F, Cellier D, et al. EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. Int J Cancer 2011; 128: 2938-46.
37. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009; 14: 399-411.
38. Capodanno A, Camerini A, Orlandini C, Baldini E, Resta ML, Bevilacqua G, et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol 2009; 40: 1408-17.
39. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 muta tions in non-small cell lung cancers. Lung Cancer 2010; 69: 279-83.
40. Piguet AC, Dufour JF. PI(3)K/PTEN/AKT pathway. J Hepatol 2011; 54: 1317-9.
41. Weickhardt AJ, Tebbutt NC, Mariadason JM. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. Curr Cancer Drug Targets 2010; 10: 824-33.
42. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379-86. (Pubitemid 47243536)
43. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M, et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004; 24: 675-81. (Pubitemid 38625006)
44. Fu C, Jiang A. Generation of tolerogenic dendritic cells via the E-cadherin/beta-catenin-signaling pathway. Immunol Res 2010; 46: 72-8.
45. Lyon C, Mill C, Tsaousi A, Williams H, George S. Regulation of VSMC behavior by the cadherin-catenin complex. Front Biosci 2011; 16: 644-57.
46. Zeljko M, Pecina-Slaus N, Martic TN, Kusec V, Beros V, Tomas D. Molecular alterations of E-cadherin and beta-catenin in brain metastases. Front Biosci (Elite Ed) 2011; 3: 616-24.
47. Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, et al. Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 2011; 13: 131-44.
48. Phillips BT, Kimble J. A new look at TCF and beta-catenin through the lens of a divergent C elegans Wnt pathway. Dev Cell 2009; 17: 27-34.
49. Xiong B, Rui Y, Zhang M, Shi K, Jia S, Tian T, et al. Tob1 controls dorsal development of zebrafsh embryos by antagonizing maternal beta-catenin transcriptional activity. Dev Cell 2006; 11: 225-38. (Pubitemid 44159240)
50. Soto-Guzman A, Navarro-Tito N, Castro-Sanchez L, Martinez-Orozco R, Salazar EP. Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells. Clin Exp Metastasis 2010; 27: 505-15.
51. Sato H, Takino T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci 2010; 101: 843-7.
52. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP traffcking to invadopodia. J Cell Sci 2009; 122: 3015-24.
53. Liu W, Zhou Y, Reske SN, Shen C. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 2008; 28: 3613-9.
54. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumori-genesis. Adv Cancer Res 2009; 102: 19-65.
55. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 2004; 23: 6788-97. (Pubitemid 39280010)
56. Poon JS, Eves R, Mak AS. Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 2010; 9: 4450-4.